Who are Endocrine therapy + Abemaciclib's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/endocrine-therapy-abemaciclib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Endocrine therapy + Abemaciclib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endocrine therapy + Abemaciclib (Endocrine therapy + Abemaciclib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK4/6 inhibitor + endocrine therapy combination. Area: Oncology.

phase 3 CDK4/6 inhibitor + endocrine therapy combination CDK4/6 (abemaciclib component); estrogen receptor (endocrine therapy component) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Endocrine therapy + Abemaciclib (Endocrine therapy + Abemaciclib) — Japanese Foundation for Cancer Research. Endocrine therapy combined with abemaciclib (a CDK4/6 inhibitor) blocks estrogen signaling and cell-cycle progression to inhibit hormone receptor-positive breast cancer growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Endocrine therapy + Abemaciclib TARGET	Endocrine therapy + Abemaciclib	Japanese Foundation for Cancer Research	phase 3	CDK4/6 inhibitor + endocrine therapy combination	CDK4/6 (abemaciclib component); estrogen receptor (endocrine therapy component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK4/6 inhibitor + endocrine therapy combination class)

Japanese Foundation for Cancer Research · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Endocrine therapy + Abemaciclib — Competitive Intelligence Brief. https://druglandscape.com/ci/endocrine-therapy-abemaciclib. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing